top of page
bannerhome.png

Developing Life
Altering Treatments

for Patients Suffering from Rare Chronic Diseases

about.png

About Lobe Sciences

heading orangenew - Copy copy.png

We are a Pharmaceutical Development Com

We focus on groundbreaking research for the treatment of rare diseases including Chronic Cluster Headache and Sickle Cell Disease. Conjugated Psilocin (CP) is our newly patented chemical entity (NCE) being developed for Chronic Cluster Headache.

Altemia® is a medical food (MF) for inborn metabolism errors found in patients with Sickle Cell Disease.  

CHRONIC CLUSTER HEADACHE
SICKLE CELL DISEASE
bluebg.png

Lobe Science

WHO WE ARE

As an innovative biopharmaceutical company, novel treatments for rare diseases are inclusive of our focus.  Our research and development entails creating new medicine for people suffering from Chronic Cluster Headache (CCH) and proprietary medical food, especially for children suffering from the pain caused by Sickle Cell Disease (SCD).

ornagebg.png
DISEASE WE FOCUS

Our Focus

heading white new.png

The two diseases we're focused on, CCH (also known as Suicide Headache) and SCD, is due to the lack of viable treatments currently available.
The associated pains from these two diseases are considered some of the most unbearable and unimaginable.
 

bg-copy-0.png

Our Structure

heading orangenew - Copy copy.png

  • Stand-alone Delaware company

  • Separate Board of Directors

  • 64% owned by Lobe Sciences, Ltd.

  • Shared services provided by Lobe under Shared Services Agreement

  • Conjugated Psilocin TM Assets and IP transferred from Lobe Sciences

logo2.png

  • Stand-alone operating company

  • Separate Executive Team

  • Shared services provided by Lobe under MSA

  • Medical food for dietary management of sickle cell disease in adult and pediatric patients, diabetes, chronic kidney disease

Subscribe to Our Newsletter

cta.png

Get in Touch with Us

CONTACT US
bottom of page